Treatment outcome and safety of durvalumab after concurrent chemoradiation in very elderly patients with unresectable stage III non-small cell lung cancer.

ABSTRACT:

Background

Consolidation durvalumab after concurrent chemoradiotherapy (CCRT) has shown a significantly improved progression-free survival (PFS) and overall survival (OS) in patients with unresectable stage III non-small cell lung cancer (NSCLC). However, data on very elderly patients remain limited. This study evaluated the outcomes and safety of durvalumab after CCRT in very elderly patients compared to younger individuals.

Methods

We reviewed all unresectable stage III patients with NSCLC treated with durvalumab after CCRT from 2020 to 2024 at four Korean hospitals. Patients were divided into two groups: aged <75 years and ≥75 years. Subgroup analyses using 65- and 70-year cutoffs were also performed. Endpoints included PFS, OS, and adverse events (AEs).

Results

Am

SUBMITTER: Kim SJ 

PROVIDER: S-EPMC12605558 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature